Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date
European Patent Office: These 77 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027
The content of this page is licensed under a Creative Commons Attribution 4.0 International License.
Generic Entry Dates in Other Countries
Friedman, Yali, "European Patent Office: These 77 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can BYDUREON (exenatide synthetic) generic drug versions launch in the European Patent Office?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: European Patent Office Patent 2,069,374
This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON
See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.
When can BYDUREON (exenatide synthetic) generic drug versions launch in the European Patent Office?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: European Patent Office Patent 3,045,466
This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON
See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.
When can BYDUREON (exenatide synthetic) generic drug versions launch in the European Patent Office?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: European Patent Office Patent 3,363,807
This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON
See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch in the European Patent Office?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: European Patent Office Patent 2,069,374
This drug has four hundred and twenty-seven patent family members in fifty-three countries. There has been litigation on patents covering FARXIGA
See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch in the European Patent Office?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: European Patent Office Patent 3,045,466
This drug has four hundred and twenty-seven patent family members in fifty-three countries. There has been litigation on patents covering FARXIGA
See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch in the European Patent Office?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: European Patent Office Patent 3,363,807
This drug has four hundred and twenty-seven patent family members in fifty-three countries. There has been litigation on patents covering FARXIGA
See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch in the European Patent Office?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: European Patent Office Patent 2,069,374
This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN
See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch in the European Patent Office?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: European Patent Office Patent 3,045,466
This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN
See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch in the European Patent Office?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: European Patent Office Patent 3,363,807
This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN
See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can EVOTAZ (atazanavir sulfate; cobicistat) generic drug versions launch in the European Patent Office?
Generic name: atazanavir sulfate; cobicistat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2026
Generic Entry Controlled by: European Patent Office Patent 2,170,851
Patent Title: MODULATEURS DES PROPRIÉTÉS PHARMACOCINÉTIQUES DE SUBSTANCES THÉRAPEUTIQUES (MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS)
This drug has three hundred and six patent family members in forty-one countries. There has been litigation on patents covering EVOTAZ
See drug price trends for EVOTAZ.
The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the atazanavir sulfate; cobicistat profile page.
When can EVOTAZ (atazanavir sulfate; cobicistat) generic drug versions launch in the European Patent Office?
Generic name: atazanavir sulfate; cobicistat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2026
Generic Entry Controlled by: European Patent Office Patent 2,487,162
Patent Title: Modulateurs de propriétés pharmacocinétiques d'agents thérapeutiques (Modulators of pharmacokinetic properties of therapeutics)
This drug has three hundred and six patent family members in forty-one countries. There has been litigation on patents covering EVOTAZ
See drug price trends for EVOTAZ.
The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the atazanavir sulfate; cobicistat profile page.
When can EVOTAZ (atazanavir sulfate; cobicistat) generic drug versions launch in the European Patent Office?
Generic name: atazanavir sulfate; cobicistat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2026
Generic Entry Controlled by: European Patent Office Patent 2,487,164
Patent Title: Modulateurs de propriétés pharmacocinétiques d'agents thérapeutiques (Modulators of pharmacokinetic properties of therapeutics)
This drug has three hundred and six patent family members in forty-one countries. There has been litigation on patents covering EVOTAZ
See drug price trends for EVOTAZ.
The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the atazanavir sulfate; cobicistat profile page.
When can EVOTAZ (atazanavir sulfate; cobicistat) generic drug versions launch in the European Patent Office?
Generic name: atazanavir sulfate; cobicistat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2026
Generic Entry Controlled by: European Patent Office Patent 2,487,165
Patent Title: Modulateurs de propriétés pharmacocinétiques d'agents thérapeutiques (Modulators of pharmacokinetic properties of therapeutics)
This drug has three hundred and six patent family members in forty-one countries. There has been litigation on patents covering EVOTAZ
See drug price trends for EVOTAZ.
The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the atazanavir sulfate; cobicistat profile page.
When can EVOTAZ (atazanavir sulfate; cobicistat) generic drug versions launch in the European Patent Office?
Generic name: atazanavir sulfate; cobicistat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2026
Generic Entry Controlled by: European Patent Office Patent 2,487,167
Patent Title: Modulateurs de propriétés pharmacocinétiques d'agents thérapeutiques (Modulators of pharmacokinetic properties of therapeutics)
This drug has three hundred and six patent family members in forty-one countries. There has been litigation on patents covering EVOTAZ
See drug price trends for EVOTAZ.
The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the atazanavir sulfate; cobicistat profile page.
When can EVOTAZ (atazanavir sulfate; cobicistat) generic drug versions launch in the European Patent Office?
Generic name: atazanavir sulfate; cobicistat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2026
Generic Entry Controlled by: European Patent Office Patent 3,112,355
Patent Title: MODULATEURS DE PROPRIÉTÉS PHARMACOCINÉTIQUES D'AGENTS THÉRAPEUTIQUES (MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS)
This drug has three hundred and six patent family members in forty-one countries. There has been litigation on patents covering EVOTAZ
See drug price trends for EVOTAZ.
The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the atazanavir sulfate; cobicistat profile page.
When can EVOTAZ (atazanavir sulfate; cobicistat) generic drug versions launch in the European Patent Office?
Generic name: atazanavir sulfate; cobicistat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2026
Generic Entry Controlled by: European Patent Office Patent 3,150,586
Patent Title: MODULATEURS DE PROPRIÉTÉS PHARMACOCINÉTIQUES D'AGENTS THÉRAPEUTIQUES (MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS)
This drug has three hundred and six patent family members in forty-one countries. There has been litigation on patents covering EVOTAZ
See drug price trends for EVOTAZ.
The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the atazanavir sulfate; cobicistat profile page.
When can EVOTAZ (atazanavir sulfate; cobicistat) generic drug versions launch in the European Patent Office?
Generic name: atazanavir sulfate; cobicistat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2026
Generic Entry Controlled by: European Patent Office Patent 3,689,353
Patent Title: MODULATEURS DE PROPRIÉTÉS PHARMACOCINÉTIQUES D'AGENTS THÉRAPEUTIQUES (MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS)
This drug has three hundred and six patent family members in forty-one countries. There has been litigation on patents covering EVOTAZ
See drug price trends for EVOTAZ.
The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the atazanavir sulfate; cobicistat profile page.
When can EVOTAZ (atazanavir sulfate; cobicistat) generic drug versions launch in the European Patent Office?
Generic name: atazanavir sulfate; cobicistat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2026
Generic Entry Controlled by: European Patent Office Patent 4,403,221
This drug has three hundred and six patent family members in forty-one countries. There has been litigation on patents covering EVOTAZ
See drug price trends for EVOTAZ.
The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the atazanavir sulfate; cobicistat profile page.
When can EVOTAZ (atazanavir sulfate; cobicistat) generic drug versions launch in the European Patent Office?
Generic name: atazanavir sulfate; cobicistat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2026
Generic Entry Controlled by: European Patent Office Patent 4,566,670
This drug has three hundred and six patent family members in forty-one countries. There has been litigation on patents covering EVOTAZ
See drug price trends for EVOTAZ.
The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the atazanavir sulfate; cobicistat profile page.
When can EPIDUO (adapalene; benzoyl peroxide) generic drug versions launch in the European Patent Office?
Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 13, 2026
Generic Entry Controlled by: European Patent Office Patent 2,046,318
Patent Title: Combinaison d'adapalène et de peroxyde de benzoyle pour le traitement de lésions inflammatoires de l'acné (Combination of adapalene and benzoyl peroxide for treating inflammatory acne lesions)
This drug has thirty-five patent family members in twenty-two countries. There has been litigation on patents covering EPIDUO
See drug price trends for EPIDUO.
The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.
When can EPIDUO (adapalene; benzoyl peroxide) generic drug versions launch in the European Patent Office?
Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 13, 2026
Generic Entry Controlled by: European Patent Office Patent 2,450,035
Patent Title: Combinaison d'adapalène et de péroxyde de benzoyle dans le traitement des lésions acnéiques (Combination of adapalene and benzoyl peroxide for treating acne lesions)
This drug has thirty-five patent family members in twenty-two countries. There has been litigation on patents covering EPIDUO
See drug price trends for EPIDUO.
The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.
When can EPIDUO FORTE (adapalene; benzoyl peroxide) generic drug versions launch in the European Patent Office?
Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 13, 2026
Generic Entry Controlled by: European Patent Office Patent 2,046,318
Patent Title: Combinaison d'adapalène et de peroxyde de benzoyle pour le traitement de lésions inflammatoires de l'acné (Combination of adapalene and benzoyl peroxide for treating inflammatory acne lesions)
This drug has thirty-five patent family members in twenty-two countries. There has been litigation on patents covering EPIDUO FORTE
See drug price trends for EPIDUO FORTE.
The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.
When can EPIDUO FORTE (adapalene; benzoyl peroxide) generic drug versions launch in the European Patent Office?
Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 13, 2026
Generic Entry Controlled by: European Patent Office Patent 2,450,035
Patent Title: Combinaison d'adapalène et de péroxyde de benzoyle dans le traitement des lésions acnéiques (Combination of adapalene and benzoyl peroxide for treating acne lesions)
This drug has thirty-five patent family members in twenty-two countries. There has been litigation on patents covering EPIDUO FORTE
See drug price trends for EPIDUO FORTE.
The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.
When can RASUVO (methotrexate) generic drug versions launch in the European Patent Office?
Generic name: methotrexate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 21, 2026
Generic Entry Controlled by: European Patent Office Patent 2,046,332
This drug has twenty-nine patent family members in twenty-one countries. There has been litigation on patents covering RASUVO
See drug price trends for RASUVO.
The generic ingredient in RASUVO is methotrexate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.
When can RASUVO (methotrexate) generic drug versions launch in the European Patent Office?
Generic name: methotrexate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 21, 2026
Generic Entry Controlled by: European Patent Office Patent 2,292,235
This drug has twenty-nine patent family members in twenty-one countries. There has been litigation on patents covering RASUVO
See drug price trends for RASUVO.
The generic ingredient in RASUVO is methotrexate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.
When can OLYSIO (simeprevir sodium) generic drug versions launch in the European Patent Office?
Generic name: simeprevir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 28, 2026
Generic Entry Controlled by: European Patent Office Patent 2,322,516
Patent Title: Composés intermédiaires pour la préparation d'inhibiteurs macrocycliques du virus de l'hépatite C (Intermediates for the preparation of Macrocyclic inhibitors of hepatitis c virus)
OLYSIO is a drug marketed by Janssen Prods. There are eight patents protecting this drug.
This drug has sixty-four patent family members in forty-one countries. There has been litigation on patents covering OLYSIO
See drug price trends for OLYSIO.
The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.
When can OLYSIO (simeprevir sodium) generic drug versions launch in the European Patent Office?
Generic name: simeprevir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 28, 2026
Generic Entry Controlled by: European Patent Office Patent 2,937,339
Patent Title: Inhibiteurs macrocycliques du virus de l'hépatite C (Macrocylic inhibitors of hepatitis c virus)
OLYSIO is a drug marketed by Janssen Prods. There are eight patents protecting this drug.
This drug has sixty-four patent family members in forty-one countries. There has been litigation on patents covering OLYSIO
See drug price trends for OLYSIO.
The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.
When can SALONPAS (menthol; methyl salicylate) generic drug versions launch in the European Patent Office?
Generic name: menthol; methyl salicylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 04, 2026
Generic Entry Controlled by: European Patent Office Patent 2,047,845
Patent Title: PRÉPARATION ADHÉSIVE (ADHESIVE PREPARATION)
SALONPAS is a drug marketed by Hisamitsu Pharm Co. There are two patents protecting this drug.
This drug has twenty patent family members in sixteen countries.
The generic ingredient in SALONPAS is menthol; methyl salicylate. There are eighteen drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the menthol; methyl salicylate profile page.
When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch in the European Patent Office?
Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 11, 2026
Generic Entry Controlled by: European Patent Office Patent 2,049,522
Patent Title: INHIBITEURS DU VIRUS DE L'HÉPATITE C (HEPATITIS C VIRUS INHIBITORS)
This drug has ninety-three patent family members in thirty-one countries. There has been litigation on patents covering DAKLINZA
See drug price trends for DAKLINZA.
The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. There are five drug master file entries for this API. Additional details are available on the daclatasvir dihydrochloride profile page.
When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch in the European Patent Office?
Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 11, 2026
Generic Entry Controlled by: European Patent Office Patent 2,385,048
Patent Title: Inhibiteurs du virus de l'hépatite C (Hepatitis C virus inhibitors)
This drug has ninety-three patent family members in thirty-one countries. There has been litigation on patents covering DAKLINZA
See drug price trends for DAKLINZA.
The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. There are five drug master file entries for this API. Additional details are available on the daclatasvir dihydrochloride profile page.
When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch in the European Patent Office?
Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 11, 2026
Generic Entry Controlled by: European Patent Office Patent 2,784,075
Patent Title: Inhibiteurs du virus de l'hépatite C (Hepatitis C virus inhibitors)
This drug has ninety-three patent family members in thirty-one countries. There has been litigation on patents covering DAKLINZA
See drug price trends for DAKLINZA.
The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. There are five drug master file entries for this API. Additional details are available on the daclatasvir dihydrochloride profile page.
When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch in the European Patent Office?
Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 11, 2026
Generic Entry Controlled by: European Patent Office Patent 3,042,901
Patent Title: INHIBITEURS DU VIRUS DE L'HEPATITE C (HEPATITIS C VIRUS INHIBITORS)
This drug has ninety-three patent family members in thirty-one countries. There has been litigation on patents covering DAKLINZA
See drug price trends for DAKLINZA.
The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. There are five drug master file entries for this API. Additional details are available on the daclatasvir dihydrochloride profile page.
When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch in the European Patent Office?
Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 11, 2026
Generic Entry Controlled by: European Patent Office Patent 3,321,263
Patent Title: COMPOSÉS POUR LA PRÉPARATION D'INHIBITEURS DU VIRUS DE L'HÉPATITE C (COMPOUNDS FOR PREPARING HEPATITIS C VIRUS INHIBITORS)
This drug has ninety-three patent family members in thirty-one countries. There has been litigation on patents covering DAKLINZA
See drug price trends for DAKLINZA.
The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. There are five drug master file entries for this API. Additional details are available on the daclatasvir dihydrochloride profile page.
When can BRILINTA (ticagrelor) generic drug versions launch in the European Patent Office?
Generic name: ticagrelor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 21, 2026
Generic Entry Controlled by: European Patent Office Patent 2,056,832
This drug has sixty-two patent family members in thirty-five countries. There has been litigation on patents covering BRILINTA
See drug price trends for BRILINTA.
The generic ingredient in BRILINTA is ticagrelor. There are twenty-one drug master file entries for this API. Twenty-seven suppliers are listed for this generic product. Additional details are available on the ticagrelor profile page.
When can LIVDELZI (seladelpar lysine) generic drug versions launch in the European Patent Office?
Generic name: seladelpar lysine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 13, 2026
Generic Entry Controlled by: European Patent Office Patent 1,937,065
LIVDELZI is a drug marketed by Gilead Sciences Inc. There are six patents protecting this drug.
This drug has one hundred and thirty-eight patent family members in forty-six countries.
The generic ingredient in LIVDELZI is seladelpar lysine. One supplier is listed for this generic product. Additional details are available on the seladelpar lysine profile page.
When can ESBRIET (pirfenidone) generic drug versions launch in the European Patent Office?
Generic name: pirfenidone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2026
Generic Entry Controlled by: European Patent Office Patent 1,940,364
ESBRIET is a drug marketed by Legacy Pharma. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-six patent family members in forty-six countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can ESBRIET (pirfenidone) generic drug versions launch in the European Patent Office?
Generic name: pirfenidone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2026
Generic Entry Controlled by: European Patent Office Patent 2,431,025
ESBRIET is a drug marketed by Legacy Pharma. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-six patent family members in forty-six countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can ZUNVEYL (benzgalantamine gluconate) generic drug versions launch in the European Patent Office?
Generic name: benzgalantamine gluconate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2026
Generic Entry Controlled by: European Patent Office Patent 1,940,817
Patent Title: AMPLIFICATEURS CHOLINERGIQUES DE PERMÉABILITÉ DE LA BARRIÈRE SANG-CERVEAU AMÉLIORÉE POUR LE TRAITEMENT DE MALADIES ACCOMPAGNÉES D'UNE DÉFICIENCE COGNITIVE (CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT)
ZUNVEYL is a drug marketed by Alpha Cognition. There are four patents protecting this drug.
This drug has twenty-seven patent family members in eighteen countries. There has been litigation on patents covering ZUNVEYL
The generic ingredient in ZUNVEYL is benzgalantamine gluconate. One supplier is listed for this generic product. Additional details are available on the benzgalantamine gluconate profile page.
When can CRESEMBA (isavuconazonium sulfate) generic drug versions launch in the European Patent Office?
Generic name: isavuconazonium sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 25, 2026
Generic Entry Controlled by: European Patent Office Patent 1,902,708
Patent Title: Compositions pharmaceutiques stabilisées et solides contenant au moins un médicament et procédé d'élaboration (Drug comprising stabilized pharmaceutical solid compositions and processes for their preparation)
This drug has thirty-two patent family members in nineteen countries. There has been litigation on patents covering CRESEMBA
See drug price trends for CRESEMBA.
The generic ingredient in CRESEMBA is isavuconazonium sulfate. One supplier is listed for this generic product. Additional details are available on the isavuconazonium sulfate profile page.
When can CRESEMBA (isavuconazonium sulfate) generic drug versions launch in the European Patent Office?
Generic name: isavuconazonium sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 25, 2026
Generic Entry Controlled by: European Patent Office Patent 2,068,842
Patent Title: FORMES GALÉNIQUES SOLIDES STABILISÉES CONTENANT UN PRINCIPE ACTIF ET DICITRATE DU TRIMAGNÉSIUM COMME DESSICCATEUR ET LEUR PROCÉDÉ DE PRODUCTION (ACTIVE INGREDIENT AND TRIMAGNESIUMDICITRATE AS DESICCANT CONTAINING STABILISED SOLID MEDICINAL FORMS AND METHOD FOR THE PRODUCTION THEREOF)
This drug has thirty-two patent family members in nineteen countries. There has been litigation on patents covering CRESEMBA
See drug price trends for CRESEMBA.
The generic ingredient in CRESEMBA is isavuconazonium sulfate. One supplier is listed for this generic product. Additional details are available on the isavuconazonium sulfate profile page.
When can TYMLOS (abaloparatide) generic drug versions launch in the European Patent Office?
Generic name: abaloparatide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: European Patent Office Patent 2,073,789
Patent Title: COMPOSITION STABLE D'UNE PROTÉINE ANABOLIQUE OSSEUSE QUI EST UN ANALOGUE DE PTHRP, ET SES EMPLOIS (A STABLE COMPOSITION COMPRISING A BONE ANABOLIC PROTEIN, NAMELY A PTHRP ANALOGUE, AND USES THEREOF)
This drug has fifty-six patent family members in twenty-nine countries. There has been litigation on patents covering TYMLOS
See drug price trends for TYMLOS.
The generic ingredient in TYMLOS is abaloparatide. One supplier is listed for this generic product. Additional details are available on the abaloparatide profile page.
When can TYMLOS (abaloparatide) generic drug versions launch in the European Patent Office?
Generic name: abaloparatide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: European Patent Office Patent 2,957,278
Patent Title: COMPOSITIONS STABLES CONTENANT PTHRP ET LEUR EMPLOI (A STABLE COMPOSITION COMPRISING PTHRP AND USES THEREOF)
This drug has fifty-six patent family members in twenty-nine countries. There has been litigation on patents covering TYMLOS
See drug price trends for TYMLOS.
The generic ingredient in TYMLOS is abaloparatide. One supplier is listed for this generic product. Additional details are available on the abaloparatide profile page.
When can COTELLIC (cobimetinib fumarate) generic drug versions launch in the European Patent Office?
Generic name: cobimetinib fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: European Patent Office Patent 1,934,174
COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.
This drug has two hundred and seven patent family members in forty-six countries.
See drug price trends for COTELLIC.
The generic ingredient in COTELLIC is cobimetinib fumarate. One supplier is listed for this generic product. Additional details are available on the cobimetinib fumarate profile page.
When can INREBIC (fedratinib hydrochloride) generic drug versions launch in the European Patent Office?
Generic name: fedratinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 26, 2026
Generic Entry Controlled by: European Patent Office Patent 1,951,684
INREBIC is a drug marketed by Bristol-myers. There are five patents protecting this drug.
This drug has one hundred and nineteen patent family members in forty-two countries. There has been litigation on patents covering INREBIC
See drug price trends for INREBIC.
The generic ingredient in INREBIC is fedratinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the fedratinib hydrochloride profile page.
When can BEVYXXA (betrixaban) generic drug versions launch in the European Patent Office?
Generic name: betrixaban
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2026
Generic Entry Controlled by: European Patent Office Patent 1,948,608
Patent Title: SELS PHARMACEUTIQUES ET POLYMORPHES DU N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO)IMINOMETHYL]BENZOYL]AMINO]-5-METHOXY-BENZAMIDE, UN INHIBITEUR DU FACTEUR X (PHARMACEUTICAL SALTS AND POLYMORPHS OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO)IMINOMETHYL]BENZOYL]AMINO]-5-METHOXY-BENZAMIDE , A FACTOR XA INHIBITOR)
BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug.
This drug has sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering BEVYXXA
See drug price trends for BEVYXXA.
The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.
When can PYLARIFY (piflufolastat f-18) generic drug versions launch in the European Patent Office?
Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: European Patent Office Patent 3,335,736
PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.
This drug has one hundred and sixteen patent family members in twenty-seven countries.
See drug price trends for PYLARIFY.
The generic ingredient in PYLARIFY is piflufolastat f-18. One supplier is listed for this generic product. Additional details are available on the piflufolastat f-18 profile page.
When can PYLARIFY (piflufolastat f-18) generic drug versions launch in the European Patent Office?
Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: European Patent Office Patent 3,699,162
PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.
This drug has one hundred and sixteen patent family members in twenty-seven countries.
See drug price trends for PYLARIFY.
The generic ingredient in PYLARIFY is piflufolastat f-18. One supplier is listed for this generic product. Additional details are available on the piflufolastat f-18 profile page.
When can PYLARIFY (piflufolastat f-18) generic drug versions launch in the European Patent Office?
Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: European Patent Office Patent 4,023,624
PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.
This drug has one hundred and sixteen patent family members in twenty-seven countries.
See drug price trends for PYLARIFY.
The generic ingredient in PYLARIFY is piflufolastat f-18. One supplier is listed for this generic product. Additional details are available on the piflufolastat f-18 profile page.
When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in the European Patent Office?
Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: European Patent Office Patent 3,335,736
PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.
This drug has one hundred and sixteen patent family members in twenty-seven countries.
The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. One supplier is listed for this generic product. Additional details are available on the piflufolastat f-18 profile page.
When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in the European Patent Office?
Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: European Patent Office Patent 3,699,162
PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.
This drug has one hundred and sixteen patent family members in twenty-seven countries.
The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. One supplier is listed for this generic product. Additional details are available on the piflufolastat f-18 profile page.
When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in the European Patent Office?
Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: European Patent Office Patent 4,023,624
PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.
This drug has one hundred and sixteen patent family members in twenty-seven countries.
The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. One supplier is listed for this generic product. Additional details are available on the piflufolastat f-18 profile page.
When can KORSUVA (difelikefalin acetate) generic drug versions launch in the European Patent Office?
Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: European Patent Office Patent 2,064,228
KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.
This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA
See drug price trends for KORSUVA.
The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.
When can KORSUVA (difelikefalin acetate) generic drug versions launch in the European Patent Office?
Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: European Patent Office Patent 2,079,756
KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.
This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA
See drug price trends for KORSUVA.
The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.
When can SOFDRA (sofpironium bromide) generic drug versions launch in the European Patent Office?
Generic name: sofpironium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 13, 2026
Generic Entry Controlled by: European Patent Office Patent 1,948,596
SOFDRA is a drug marketed by Botanix Sb. There are twenty patents protecting this drug.
This drug has one hundred and sixty-five patent family members in twenty-six countries. There has been litigation on patents covering SOFDRA
The generic ingredient in SOFDRA is sofpironium bromide. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the sofpironium bromide profile page.
When can SOFDRA (sofpironium bromide) generic drug versions launch in the European Patent Office?
Generic name: sofpironium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 13, 2026
Generic Entry Controlled by: European Patent Office Patent 1,957,451
SOFDRA is a drug marketed by Botanix Sb. There are twenty patents protecting this drug.
This drug has one hundred and sixty-five patent family members in twenty-six countries. There has been litigation on patents covering SOFDRA
The generic ingredient in SOFDRA is sofpironium bromide. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the sofpironium bromide profile page.
When can AXUMIN (fluciclovine f-18) generic drug versions launch in the European Patent Office?
Generic name: fluciclovine f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: European Patent Office Patent 1,978,015
Patent Title: COMPOSE PRECURSEUR DE COMPOSE ORGANIQUE MARQUE A L'HALOGENE RADIOACTIF (PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN LABELED ORGANIC COMPOUND)
AXUMIN is a drug marketed by Blue Earth. There are eight patents protecting this drug.
This drug has thirty patent family members in sixteen countries. There has been litigation on patents covering AXUMIN
The generic ingredient in AXUMIN is fluciclovine f-18. One supplier is listed for this generic product. Additional details are available on the fluciclovine f-18 profile page.
When can ZTALMY (ganaxolone) generic drug versions launch in the European Patent Office?
Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: European Patent Office Patent 1,959,966
Patent Title: FORMES GALÉNIQUES DE GANAXOLONE ET PROCÉDÉS DE PREPARATION ET D'UTILISATION DE CELLES-CI (GANAXOLONE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF)
ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug.
This drug has forty-nine patent family members in sixteen countries. There has been litigation on patents covering ZTALMY
See drug price trends for ZTALMY.
The generic ingredient in ZTALMY is ganaxolone. One supplier is listed for this generic product. Additional details are available on the ganaxolone profile page.
When can ZUBSOLV (buprenorphine hydrochloride; naloxone hydrochloride) generic drug versions launch in the European Patent Office?
Generic name: buprenorphine hydrochloride; naloxone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: European Patent Office Patent 2,101,740
Patent Title: NOUVELLE COMPOSITION PHARMACEUTIQUE NON SUSCEPTIBLE D'ABUS COMPRENANT DES OPIOÏDES (NEW NON-ABUSABLE PHARMACEUTICAL COMPOSITION COMPRISING OPIOIDS)
This drug has sixty-two patent family members in thirty-two countries. There has been litigation on patents covering ZUBSOLV
See drug price trends for ZUBSOLV.
The generic ingredient in ZUBSOLV is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this API. Twenty-nine suppliers are listed for this generic product. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.
When can SIRTURO (bedaquiline fumarate) generic drug versions launch in the European Patent Office?
Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: European Patent Office Patent 2,086,940
SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.
This drug has ninety-seven patent family members in thirty-nine countries.
See drug price trends for SIRTURO.
The generic ingredient in SIRTURO is bedaquiline fumarate. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the bedaquiline fumarate profile page.
When can ZYKADIA (ceritinib) generic drug versions launch in the European Patent Office?
Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: European Patent Office Patent 2,091,918
ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.
This drug has three hundred and twenty-two patent family members in fifty-six countries.
See drug price trends for ZYKADIA.
The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.
When can ZYKADIA (ceritinib) generic drug versions launch in the European Patent Office?
Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: European Patent Office Patent 2,190,826
ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.
This drug has three hundred and twenty-two patent family members in fifty-six countries.
See drug price trends for ZYKADIA.
The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.
When can ZYKADIA (ceritinib) generic drug versions launch in the European Patent Office?
Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: European Patent Office Patent 2,311,807
ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.
This drug has three hundred and twenty-two patent family members in fifty-six countries.
See drug price trends for ZYKADIA.
The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.
When can ZYKADIA (ceritinib) generic drug versions launch in the European Patent Office?
Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: European Patent Office Patent 2,537,830
ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.
This drug has three hundred and twenty-two patent family members in fifty-six countries.
See drug price trends for ZYKADIA.
The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.
When can ZYKADIA (ceritinib) generic drug versions launch in the European Patent Office?
Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: European Patent Office Patent 3,012,249
ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.
This drug has three hundred and twenty-two patent family members in fifty-six countries.
See drug price trends for ZYKADIA.
The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.
When can LETAIRIS (ambrisentan) generic drug versions launch in the European Patent Office?
Generic name: ambrisentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: European Patent Office Patent 2,101,777
Patent Title: COMPOSITION DE TRAITEMENT DE L'HYPERTENSION PULMONAIRE (COMPOSITION FOR TREATING A PULMONARY HYPERTENSION)
LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-one patent family members in twenty-six countries. There has been litigation on patents covering LETAIRIS
See drug price trends for LETAIRIS.
The generic ingredient in LETAIRIS is ambrisentan. There are nine drug master file entries for this API. Thirteen suppliers are listed for this generic product. Additional details are available on the ambrisentan profile page.
When can XERMELO (telotristat etiprate) generic drug versions launch in the European Patent Office?
Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: European Patent Office Patent 2,091,940
XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.
This drug has seventy patent family members in twenty-nine countries.
See drug price trends for XERMELO.
The generic ingredient in XERMELO is telotristat etiprate. One supplier is listed for this generic product. Additional details are available on the telotristat etiprate profile page.
When can XERMELO (telotristat etiprate) generic drug versions launch in the European Patent Office?
Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: European Patent Office Patent 2,589,600
XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.
This drug has seventy patent family members in twenty-nine countries.
See drug price trends for XERMELO.
The generic ingredient in XERMELO is telotristat etiprate. One supplier is listed for this generic product. Additional details are available on the telotristat etiprate profile page.
When can XERMELO (telotristat etiprate) generic drug versions launch in the European Patent Office?
Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: European Patent Office Patent 3,808,740
XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.
This drug has seventy patent family members in twenty-nine countries.
See drug price trends for XERMELO.
The generic ingredient in XERMELO is telotristat etiprate. One supplier is listed for this generic product. Additional details are available on the telotristat etiprate profile page.
When can PICATO (ingenol mebutate) generic drug versions launch in the European Patent Office?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: European Patent Office Patent 2,399,571
Patent Title: Compositions thérapeutiques comprenant de l'ingénol-2-angelate (Therapeutic compositions comprising ingenol-3-angelate)
This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.
When can VYKAT XR (diazoxide choline) generic drug versions launch in the European Patent Office?
Generic name: diazoxide choline
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2026
Generic Entry Controlled by: European Patent Office Patent 1,968,601
Patent Title: SELS D'OUVREURS DES CANAUX POTASSIQUES ATP-DÉPENDANTS ET LEURS UTILISATIONS (SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF)
VYKAT XR is a drug marketed by Soleno Therap. There are six patents protecting this drug.
This drug has seventy-nine patent family members in twenty-two countries.
The generic ingredient in VYKAT XR is diazoxide choline. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the diazoxide choline profile page.
When can VYKAT XR (diazoxide choline) generic drug versions launch in the European Patent Office?
Generic name: diazoxide choline
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2026
Generic Entry Controlled by: European Patent Office Patent 2,404,604
Patent Title: Sels d'ouverture de canal ATP du potassium et leurs utilisations (Salts of potassium ATP channel openers and uses thereof)
VYKAT XR is a drug marketed by Soleno Therap. There are six patents protecting this drug.
This drug has seventy-nine patent family members in twenty-two countries.
The generic ingredient in VYKAT XR is diazoxide choline. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the diazoxide choline profile page.
When can SEYSARA (sarecycline hydrochloride) generic drug versions launch in the European Patent Office?
Generic name: sarecycline hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2026
Generic Entry Controlled by: European Patent Office Patent 2,120,963
Patent Title: UTILISATION DE COMPOSÉS À BASE DE TÉTRACYCLINE SUBSTITUÉE DANS LE TRAITEMENT D'AFFECTIONS CUTANÉES INFLAMMATOIRES (SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY SKIN DISORDERS)
SEYSARA is a drug marketed by Almirall. There are four patents protecting this drug.
This drug has seventy-two patent family members in twenty countries.
See drug price trends for SEYSARA.
The generic ingredient in SEYSARA is sarecycline hydrochloride. One supplier is listed for this generic product. Additional details are available on the sarecycline hydrochloride profile page.
When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in the European Patent Office?
Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: European Patent Office Patent 2,495,016
ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has one hundred and nine patent family members in twenty-four countries. There has been litigation on patents covering ICLUSIG
See drug price trends for ICLUSIG.
The generic ingredient in ICLUSIG is ponatinib hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ponatinib hydrochloride profile page.
When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in the European Patent Office?
Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: European Patent Office Patent 3,747,441
ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has one hundred and nine patent family members in twenty-four countries. There has been litigation on patents covering ICLUSIG
See drug price trends for ICLUSIG.
The generic ingredient in ICLUSIG is ponatinib hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ponatinib hydrochloride profile page.
When can EPSOLAY (benzoyl peroxide) generic drug versions launch in the European Patent Office?
Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: European Patent Office Patent 2,118,208
Patent Title: MÉTHODE DE PRÉPARATION DE PARTICULES COMPRENANT UN ENROBAGE D'OXYDE MÉTALLIQUE (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING)
This drug has fifty-one patent family members in fifteen countries. There has been litigation on patents covering EPSOLAY
See drug price trends for EPSOLAY.
The generic ingredient in EPSOLAY is benzoyl peroxide. There are seventeen drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the benzoyl peroxide profile page.
When can EPSOLAY (benzoyl peroxide) generic drug versions launch in the European Patent Office?
Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: European Patent Office Patent 2,545,776
Patent Title: Procédé de préparation de particules comprenant un revêtement d'oxyde métallique et particules à revêtement d'oxyde métallique (Method for preparing particles comprising metal oxide coating and particles with metal oxide coating)
This drug has fifty-one patent family members in fifteen countries. There has been litigation on patents covering EPSOLAY
See drug price trends for EPSOLAY.
The generic ingredient in EPSOLAY is benzoyl peroxide. There are seventeen drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the benzoyl peroxide profile page.
When can NESINA (alogliptin benzoate) generic drug versions launch in the European Patent Office?
Generic name: alogliptin benzoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: European Patent Office Patent 2,124,901
Patent Title: PRÉPARATION DE COMPRIMÉ NE PROVOQUANT PAS DE PROBLÈME DE PASTILLAGE (TABLET PREPARATION WITHOUT CAUSING A TABLETING TROUBLE)
This drug has sixty-nine patent family members in thirty-seven countries. There has been litigation on patents covering NESINA
See drug price trends for NESINA.
The generic ingredient in NESINA is alogliptin benzoate. There are ten drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate profile page.
When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in the European Patent Office?
Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: European Patent Office Patent 2,107,905
This drug has one hundred and one patent family members in forty-two countries. There has been litigation on patents covering OSENI
See drug price trends for OSENI.
The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. There are ten drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.
When can MACRILEN (macimorelin acetate) generic drug versions launch in the European Patent Office?
Generic name: macimorelin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 19, 2027
Generic Entry Controlled by: European Patent Office Patent 1,984,744
MACRILEN is a drug marketed by Aeterna Zentaris. There is one patent protecting this drug.
This drug has eleven patent family members in ten countries.
See drug price trends for MACRILEN.
The generic ingredient in MACRILEN is macimorelin acetate. Two suppliers are listed for this generic product. Additional details are available on the macimorelin acetate profile page.
When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in the European Patent Office?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: European Patent Office Patent 2,079,445
PANCREAZE is a drug marketed by
This drug has eleven patent family members in ten countries.
See drug price trends for PANCREAZE.
The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in the European Patent Office?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: European Patent Office Patent 2,079,445
ZENPEP is a drug marketed by
This drug has eleven patent family members in ten countries.
See drug price trends for ZENPEP.
The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can PRESTALIA (amlodipine besylate; perindopril arginine) generic drug versions launch in the European Patent Office?
Generic name: amlodipine besylate; perindopril arginine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 26, 2027
Generic Entry Controlled by: European Patent Office Patent 1,989,182
PRESTALIA is a drug marketed by Adhera. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has thirty patent family members in twenty-seven countries. There has been litigation on patents covering PRESTALIA
The generic ingredient in PRESTALIA is amlodipine besylate; perindopril arginine. There are fifty drug master file entries for this API. Additional details are available on the amlodipine besylate; perindopril arginine profile page.
When can DYANAVEL XR (amphetamine) generic drug versions launch in the European Patent Office?
Generic name: amphetamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2027
Generic Entry Controlled by: European Patent Office Patent 2,428,205
Patent Title: Formulations à libération modifiée contenant des complexes médicament - résine échangeuse d'ions (Modified release formulations containing drug-ion exchange resin complexes)